|
Lungentransplantation – Therapieoption bei Lungenerkrankungen im Endstadium
Deutsches Ärzteblatt In den letzten Jahren haben die Einführung der „mammalian target of rapamycin“(mTOR)-Inhibitoren (Sirolimus und Everolimus) und des Anti-CD25-Antikörpers (Daclizumab, Basiliximab – nur Induktionstherapie) die Kombinationsmöglichkeiten erweitert (24, … |
Research and Markets: Monoclonal Antibodies Market in Breast Cancer to 2019 …Business Wire (press release)The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth fa…
Rheuminations: Comparative Studies Needed for RA BiologicsMedPage TodayIn one study, SWITCH-RA, patients given rituximab rather than a second TNF inhibitor had significantly better results on disease activity scores after 6 months. However, in a study …
|
Autoimmune attack behind some cases of schizophrenia
New Scientist Previous studies had found that antibodies that target the NMDA receptor on neurons trigger brain inflammation, leading to seizures, comas – and sometimes psychosis (Annals of Neurology, doi.org/fdgnpc). In the past few years, these antibodies have … |
|
Avaxia receives US patent with broad coverage over oral anti-TNF antibodies …
pharmabiz.com 8,647,626, entitled “Compositions Comprising TNF-specific Antibodies for Oral Delivery.” This patent covers milk-derived anti-TNF antibodies that are orally administered within a broad dose range for the treatment of inflammatory bowel disease (IBD). |
|
Here’s Why Biogen Could Be in Store for a Big 2014
Motley Fool It’s been a great year for Biogen (NASDAQ: BIIB ) investors. Shares in the company have more than doubled as sales climbed more than 25% to nearly $7 billion in the past year. A lot of that success is thanks to surging sales for its new oral MS drug … |
|
Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD
News-Medical.net Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled “Compositions Comprising TNF-specific Antibodies for Oral … |
UPI.comScientists find neutralizing antibodies that protects humanized mice from HIV …News-Medical.netNIH-funded scientists have shown that boosting the production of certain broadly neutralizing antibodies can protect humanized mice from both intrav…
|
Rheuminations: Arthritis Tx the EULAR Way
MedPage Today The American College of Rheumatology (ACR) guidelines state that “if after 3 months of methotrexate monotherapy or DMARD combination therapy … the panel recommends adding or switching to an anti-TNF biologic, abatacept, or rituximab [Rituxan].”. |
Nature World NewsGenetically Mutated Mice Capable of Avoiding HIV InfectionNature World NewsMice that have been genetically reprogrammed to have human-like immune systems can be protected from HIV by boosting their production of certain broadly neutral…